1189173-29-2

Upstream product

• 1189173-27-0 3-hydroxymethyl-2-n-propylphenol 
• 183108-35-2 methyl 3-hydroxy-2-n-propylbenzoate 
• 79250-46-7 methyl 3-(prop-2-enyloxy)benzoate 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 110-87-2 3,4-dihydro-2H-pyran 
• 1189173-28-1 4-bromo-3-(hydroxymethyl)-2-n-propylphenol 

Downstream Products

• 1189173-30-5 2-((6-bromo-3-(methoxymethoxy)-2-n-propylbenzyl)oxy)tetrahydro-2H-pyran 
• 1189173-31-6 1,1,1,3,3,3-hexafluoro-2-(4-(methoxymethoxy)-3-n-propyl-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)propan-2-ol 
• 1189173-32-7 1,1,1,3,3,3-hexafluoro-2-(2-(hydroxymethyl)-4-(methoxymethoxy)-3-n-propyl-phenyl)propan-2-ol 

Relevant academic research and scientific papers

Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists

A novel series of 1,3-bistrifluoromethylcarbinol derivatives that act as liver X receptor (LXR) β-selective agonists was discovered. Structure-activity relationship studies led to the identification of molecule 62, which was more effective (Emax) and selective toward LXRβ than T0901317 and GW3965. Furthermore, 62 decreased LDL-C without elevating the plasma TG level and significantly suppressed the lipid-accumulation area in the aortic arch in a Bio F1B hamster fed a diet high in fat and cholesterol. We demonstrated that our LXRβ agonist would be potentially useful as a hypolipidemic and anti-atherosclerotic agent. In this manuscript, we report the design, synthesis and pharmacology of 1,3-bistrifluoromethylcarbinol derivatives.

1,3-DIHYDROISOBENZOFURAN DERIVATIVES

The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory d